en · de · es · fr · pt
peptide-index.peptides7501.com › Info › Detection, Regulation, And Misconceptions — 2026 Update

Detection, Regulation, And Misconceptions — 2026 Update

By Editorial Desk · published 2026-01-01 · last reviewed 2026-02-09 · Info

LC-MS/MS comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.

Updated 2026-02-09. Numbers and descriptions here follow the published literature rather than marketing material.

Detection, Regulation, and Misconceptions

Several misconceptions surround SR9009. It is often described as a SARM, a steroid, or an exercise pill, but its known target is the REV-ERB receptor family. Rodent studies have examined exercise capacity and metabolic markers, yet human outcomes remain unproven. Oral bioavailability appears low in animals, and human pharmacokinetics are not well characterized. Online products may contain impurities or different compounds, so identity and purity testing are important for research use.

Analytical chemists detect SR9009 with liquid chromatography-tandem mass spectrometry, commonly abbreviated LC-MS/MS. Sample preparation may involve protein precipitation, liquid-liquid extraction, or solid-phase extraction before analysis. Laboratories can target the parent compound or its metabolites, depending on the matrix and the purpose of testing. Anti-doping methods require sensitive and specific assays because concentrations in biological samples can be low. Reference standards and validated methods are essential for reliable identification and quantification.

Regulatory agencies have not approved SR9009 for human therapeutic use. It is typically sold as a research chemical with labels stating that it is not for human consumption. The World Anti-Doping Agency prohibits the substance in sport, generally under the category of non-approved substances. Customs and national laws may restrict importation, sale, or possession. Product quality and legal status can vary by country and vendor, and therapeutic claims are not permitted in regulated advertising because the compound lacks approval.

Analytical and Handling Considerations

SR9009 is generally described as poorly soluble in water and more soluble in organic solvents such as dimethyl sulfoxide and ethanol. Stock solutions are commonly prepared in an organic solvent before dilution into an aqueous buffer or vehicle. Precipitation can occur if the organic fraction is reduced too quickly or if the final concentration exceeds the compound's solubility limit. Sonication or gentle warming may aid dissolution in some protocols, but excessive heat can promote degradation. Container material and pH can also influence observed solubility.

For long-term storage, SR9009 is typically kept as a solid at low temperature, protected from moisture and light. Desiccated conditions limit hydrolysis, while opaque containers reduce photochemical breakdown. Solutions are less stable than solids and are often stored frozen in aliquots to avoid repeated freeze-thaw cycles. Stability data are not standardized across all suppliers, so users should rely on certificate-of-analysis information when available. Degradation may appear as color change, precipitate, or decreased chromatographic purity.

Sr9009 at a glance

PropertyValueNotes
Regulatory statusNot approved for human useResearch-use-only status in many markets
WADA statusProhibited in sportGenerally listed as a non-approved substance
Detection techniqueLC-MS/MSCommon for urine and blood analysis
Common aliasStenabolicInformal market nickname, not a pharmacopoeial name
Purity checkHPLC or LC-UVIndependent certificate of analysis is typical

Background and Pharmacological Mechanism

SR9009 is often grouped with compounds studied for circadian and metabolic regulation rather than with classical anabolic steroids. Its interactions with nuclear receptors differ from those of androgen receptor ligands, and its proposed mechanisms involve transcriptional control rather than direct hormone signaling. Some sources classify it as a metabolic modulator because of observed effects on energy utilization. The distinction matters for regulation and for interpreting research results across different compound classes.

SR9009 is a synthetic small molecule developed as a REV-ERB agonist. It binds to REV-ERBα and REV-ERBβ, nuclear receptors that help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, the compound alters lipid and glucose handling and influences skeletal muscle oxidative capacity. Its exact effects in humans remain largely uncharacterized because controlled clinical trials have not been reported. The molecule is frequently described in preclinical literature as a metabolic modulator.

Related pages on this site

Background and Receptor Pharmacology

Regulatory and sporting contexts treat SR9009 as a prohibited substance in many elite competitions. Its presence on banned lists reflects concerns about performance enhancement and unknown long-term safety. Analytical chemists have developed methods to detect the parent compound and its metabolites in urine and blood. Literature discussions distinguish between in vitro potency, animal pharmacology, and anecdotal human reports. The latter are difficult to verify because products sold online may lack purity or contain different compounds.

SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms, lipid metabolism, and inflammatory gene expression. In cell and animal experiments, SR9009 alters transcription of clock-controlled genes and metabolic pathways. The compound is not a hormone and does not resemble classical steroid structures. Its activity depends on binding to the ligand-binding domain of REV-ERB, where it can modify corepressor recruitment.

Notes from published material

==== Tolerance ==== Tolerance is a process characterized by neuroadaptations that result in reduced drug effects. While receptor upregulation may often play an important role other mechanisms are also known. Tolerance is more pronounced for some effects than for others; tolerance occurs slowly to the effects on mood, itching, urinary retention, and respiratory depression, but occurs more quickly to the analgesia and other physical side effects. However, tolerance does not develop to constipation or miosis (the constriction of the pupil of the eye to less than or equal to two millimeters). This idea has been challenged, however, with some authors arguing that tolerance does develop to miosis. Tolerance to opioids is attenuated by a number of substances, including:

A c. 1894 Gustav Hammer & Co. commercial cooking machinery catalogue. Preserving foods ~ from the Clemson Extension Home and Garden Information Center National Center for Home Food Preservation BBC News Online – US army food... just add urine Home Economics Archive: Tradition, Research, History (HEARTH) An e-book collection of over 1,000 classic books on home economics spanning 1850 to 1950, created by Cornell University's Mann Library. Pobojewski, Sally (8 May 1995). "Underwater storage techniques preserved meat for early hunters". The University Record. University of Michigan. Archived from the original on 26 February 2019. Retrieved 28 September 2018.

== Concerns == Since microbes, namely Salmonella and Bacillus cereus, can persist in IMFs, other hurdles including reduction in pH and the use of preservatives is not unusual. However, additives such as nitrites and sulfites are associated with health concerns. Nitrites have a negative connotation in the food industry since they can combine with secondary amines to form nitrosamines, which are carcinogenic. Nitrites are linked to an increase risk in cancer and heart disease. Sulfite is another additive that is commonly avoided due to people having a sensitivity to sulfites. Yeast and mold are not fully inhibited by IMF processing because these microorganisms can tolerate water activity as low as 0.80. Browning can occur during storage of Intermediate moisture fruits and vegetables. Finally, sugar used commonly added as a humectant increases the caloric value of the food.

== Efficacy == IPT has not been proven to work. Lab research indicates that there is not even a theoretical possibility of it being an effective treatment for most cancers. Research over the decades has proved that most cancers grow when exposed to more insulin. One study of men with prostate cancer showed that survival was significantly shorter (11 months for men who received IPT vs 18.9 months for men on standard treatment). A second small trial showed that women with metastatic breast cancer were less likely to see short-term disease progression if they received IPT with low-dose methotrexate than if they received either insulin alone or low-dose methotrexate alone. (This study did not compare IPT against any of the proven multi-drug chemotherapy regimens.)

Sources: en.wikipedia.org

Background from the literature

== Other effects == In concert with the primary surface forces described above, there are several circumstantial effects in play. While the forces themselves each contribute to the magnitude of the adhesion between the surfaces, the following play a crucial role in the overall strength and reliability of an adhesive device.

The NHL repeat, named after ncl-1, HT2A and lin-41, is an amino acid sequence found largely in a large number of eukaryotic and prokaryotic proteins. For example, the repeat is found in a variety of enzymes of the copper type II, ascorbate-dependent monooxygenase family which catalyse the C-terminus alpha-amidation of biological peptides. In many it occurs in tandem arrays, for example in the RING finger beta-box, coiled-coil (RBCC) eukaryotic growth regulators. The arthropod 'Brain Tumor' protein (Brat; Q8MQJ9) is one such growth regulator that contains a 6-bladed NHL-repeat beta-propeller. The NHL repeats are also found in serine/threonine protein kinase (STPK) in diverse range of pathogenic bacteria. These STPK are transmembrane receptors with an intracellular N-terminal kinase domain and extracellular C-terminal sensor domain. In the STPK, PknD, from Mycobacterium tuberculosis, the sensor domain forms a rigid, six-bladed b-propeller composed of NHL repeats with a flexible tether to the transmembrane domain. The NHL repeat has also been used to design a family of fully symmetrical 6-blade beta-propeller proteins called "Pizza". These proteins can also be engineered to bind mineral nanocrystals.

==== Agonists ==== Agmatine (putative endogenous ligand at I1; also interacts with NMDA, nicotinic, and α2 adrenoceptors) Apraclonidine (α2 adrenoceptor agonist) 2-BFI (I2 agonist, NMDA antagonist) Cimetidine (I1 agonist, H2 receptor antagonist) Clonidine (I1 agonist, α2 adrenoceptor agonist) LNP-509 LNP-911 7-Me-marsanidine Dimethyltryptamine mCPP Moxonidine Oxymetazoline (I1 agonist, α1 adrenoceptor agonist, α2 partial agonist) Rilmenidine S-23515 S-23757 Tizanidine

It was this late version (not the European ROM) that served as the basis for the port on the PC. The game was one of the first games to be released under the Disney Interactive label. By the 1996 holiday shopping season, the CD-based PlayStation and Saturn consoles had achieved a significant presence in the market, making third party publishers reluctant to spend money on expensive cartridges for consoles such as the Super NES. Because of this, Nintendo (which owned the factory where Super NES cartridges were made and thus could manufacture them more cheaply than third parties could) licensed the game from Disney Interactive and published it in North America and Europe. The game premiered for the North American market at Walt Disney World in September 1996. Three Maui Mallard kiosks were prepared in the Disney Interactive exhibit at the Innoventions plaza of EPCOT. Visitors could play the full game for an unlimited period of time and interact with Attractions Hosts and Hostesses who were available to play against them and share tips and tricks. According to composer Patrick Collins, Donald Duck's name was dropped from the North American release because the marketing team felt that "Donald Duck just isn't hip in the United States like he is in Europe".

=== ERAP1 catalytic site inhibitors === Phosphinic derivatives The first generation of ERAP1 inhibitors is a series of phosphinic pseudopeptides derived from a rational design approach targeting the catalytic zinc-binding site, in 20131. Notably, DG013A (Table 1, Figure 3) displayed high potency (ERAP1 IC50 = 33 nM) but poor selectivity against ERAP2 and IRAP, with reported SAR optimization studies demonstrating the importance of side chains at positions P1' and P2'. A high-resolution crystal structure of phosphinic analogue DG046 bound in the active site of ERAP1, has been obtained (Figure 4).

Sources: en.wikipedia.org

Frequently asked questions

Is SR9009 legal to buy?

Legality depends on the country and the intended use. In many places it is not approved as a medicine and may be sold only as a research chemical. Importation or possession can be restricted, and sports organizations prohibit it.

How is SR9009 detected in doping tests?

Anti-doping laboratories typically use LC-MS/MS to detect SR9009 or its metabolites in urine or blood. The exact assay depends on the laboratory and the testing program. Detection can be challenging because the compound may be rapidly metabolized and present at low levels.

Why is SR9009 called Stenabolic?

Stenabolic is an informal nickname used in online fitness and research-chemical markets, not an official drug name. It likely references reported effects on endurance in rodent studies. The nickname does not imply approval or proven human benefit.

How is SR9009 detected in laboratory samples?

Liquid chromatography with mass spectrometry is a common approach. Ultraviolet detection and nuclear magnetic resonance can support identification when suitable standards are available.

Network